The method of obtaining acellular dermal matrix

 

(57) Abstract:

The invention relates to medicine, in particular to methods for biological coatings for wound closure in the treatment of patients with burns and mechanical damage to the skin. The method of obtaining acellular dermal matrix includes the destruction of the cells of the dermis, extraction of the products of their decay and extracellular Nikolayevich proteins and sterilization matrix. The new method is that the dermis is placed in a 30% solution of urea with the addition of calcium chloride to 0.5% concentration at +4°C for 24 hours when the ratio of the volume of the dermis and urea solution 1:3 and then aged dermal matrix in a 20% solution of urea at room temperature for one hour. The invention provides reduction, cost reduction and simplification of the method.

The present invention relates to medicine, in particular to methods for biological coatings for wound closure in the treatment of patients with burns and mechanical damage to the skin.

As a prototype of the selected method of receiving acellular dermal matrix, including the destruction of the cells of the dermis by putting skin in the hypertonic solution hloreover extracellular proteins by sodium dodecyl sulfate or Triton X-100 and subsequent sterilization derived acellular dermal matrix (Walter R. J., Matsuda T., Reges N. M., Walter J. M., Hanumadas M. Characterization of acellular dermal matrices (ADMs) prepared by two different metods. Burns, 1998, v.24, n.2, p.104-113).

The disadvantages of this method are the length of the process, the high cost of drugs and the need to launder them before the transfer matrix to the wound.

The objective of the proposed technical solution is the reduction in the duration of the method, its cost reduction and simplification.

The problem is solved due to the fact that in the method, including the destruction of the cells of the dermis, extraction of the products of their decay and extracellular Nikolayevich proteins and sterilization matrix, put the dermis for 24 hours at +4°With a 30% solution of urea with the addition of calcium chloride to 0.5% concentration when the ratio of the volume of the dermis and urea solution 1:3, followed by exposure dermal matrix in a 20% solution of urea for 1 hour at room temperature.

The method of obtaining the acellular dermal matrix is as follows: the dermis thickness of 0.2-0.3 mm is placed in a 30% solution of urea with the addition of calcium chloride to a concentration of 0.5%. The ratio of the volume of the dermis and solution of urea of 1:3. The dermis in the urea solution will viderem 1 hour at room temperature with periodic shaking. Received acellular dermal matrix can be used for transplantation or placed on the preservation of any method used to save the skin for subsequent transplantation.

Received acellular dermal matrix eliminates the use of additional methods sterilize does not require laundering prior to transplantation, better fixed on the wound by increasing the adhesive properties and retains the ability to activate the processes of regeneration in the wound.

The method of obtaining acellular dermal matrix by breaking down the cells of the dermis, extraction of the products of their decay and extracellular Nikolayevich proteins and sterilization matrix, characterized in that place the dermis at 24 h at +4°With a 30% solution of carbamide with the addition of calcium chloride to 0.5% concentration with the ratio of the volume of the dermis and urea solution 1:3, followed by exposure dermal matrix in a 20% solution of urea for 1 h at room temperature.



 

Same patents:

The invention relates to medicine, namely to the stimulants of colony-forming cells
The invention relates to medicine, in particular for experimental medicine
The invention relates to medicine, namely to experimental medicine and surgery
The invention relates to medicine, urology, Pediatrics
The invention relates to medicine and relates to the production of purified activated factor X clotting

The invention relates to medicine and biology, more specifically a process for the production of collagen, and can be used in the treatment of various tissue pathologies, for cell cultivation

The invention relates to immunology, immunopharmacology, medical biotechnology and pharmaceutical industries, namely the method of production of immunotropic substances from pig skin

The invention relates to medicine, endocrinology
The invention relates to medicine and can be used for the preparation of a defect of the skin to the autodermoplasty

FIELD: surgical facilities.

SUBSTANCE: invention provides material suitable as hemostatic and wound-healing remedy in low-invasive internal surgery involving endoscopic techniques. Allogenic connective-tissue formations (tendons, fascias, dermis) are subjected to mechanical cleaning to remove the rests of adjoining tissues and foreign bodies, washed with running water during 5-10 min, degreased by cold (+4оС) acetone, placed for 5-10 min in 3% hydrogen peroxide solution to remove blood, and thrice rinsed with 0.9% sodium chloride solution. Treated tissues are frozen in cryogenic chamber at -45оС and dried in vacuo to constant weight using liophilic drying technique. Dried material is then wetted at 1:5 weight ratio in solution containing calculated quantities of hemostatic (fibrinogen), fibrinolysis inhibitor (aminocapronic acid), and antibiotic (cephalexin) for 10-20 min until biomaterial structure is completely and uniformly impregnated. Solution id prepared at +4оС by consecutively dissolving 0.2 g cephalexin and 1 g fibrinogen in 10 ml of 5% aminocapronic acid solution. Thereafter, biomaterial is once again frozen and subjected to liophilic drying, then ground on blade-type mill (e.g. "Cyclotec", Foss Tecator) to particle size 0.1-0.25 mm, which are packaged by 0.5 g doses into glass 20-ml bottles, tightly sealed, and sterilized by gamma radiation in dose 2.5 MRad (25 kGr).

EFFECT: simplified technology, improved quality and structure of material.

FIELD: medicine, andrology.

SUBSTANCE: boiling velvet antlers water should be applied in the form of aerosol onto "panties" area of patient's body surface in combination with dry heat thrice every other day, about 8-10 procedures/course. The innovation enables to minimize the load upon cardio-vascular system and enhance surface circulation.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine and biopharmacology.

SUBSTANCE: claimed biotransplant contains culture of genetically non-modified mesenchyme stem cells (MSC), fibroblasts including epithelial cells. Biotransplant is used in intradermal administration. Biotransplant is administered topically in physiological solution with concentration from 1 to 10 millions per 1 ml. Total transplant amount is 1-10 millions depending on defect area.

EFFECT: treatment method with high reproducibility.

14 cl

FIELD: medicine and biopharmacology.

SUBSTANCE: claimed biotransplant contains culture of genetically non-modified mesenchyme stem cells (MSC), including fibroblasts of hair follicule dermal papillae, epithelial cells including ones obtained from hair follicle stem niche. Biotransplant is used in intradermal administration. Method for alopecia treatment includes intradermal administration of biotransplant containing from 10 to 100 millions cells to patient, in procedure room by micropapulic method. Biotransplant is administered in physiological solution with concentration from 1 to 10 millions per 1 ml. Total transplant amount is 1-10 millions depending on lesion area and type of alopecia.

EFFECT: method for alopecia treatment with high reproducibility.

12 cl

FIELD: medicine.

SUBSTANCE: method involves administering Corbiculin at a dose of 2 g three times a day when prediluted with 50 ml of water. The treatment course is 21 days long or longer until alanine aminotransferase and aspartate aminotransferase indices assume normal values.

EFFECT: enhanced effectiveness in normalizing hyperenzymemia and relieving clinic manifestations of cytolytic syndrome.

2 tbl

FIELD: medicine.

SUBSTANCE: method involves administering suspension containing up to 500 thousand of fibroblasts introduced on 50 to 400 mcm large microspheres as injections into connective tissue.

EFFECT: enhanced effectiveness in treating for periodontitis, age-specific skin defects, fistulas, wounds and ureteral reflux.

4 cl

FIELD: medicine.

SUBSTANCE: one should place bioplastic material in culture liquid with a culture of dermal fibroblasts to cultivate fibroblasts together with bioplastic material for 4 d, then it is necessary to sample culture liquid and detect the concentration of protein-bound hydroxyproline. One concludes upon the degree of collagenogenesis stimulation with tested bioplastic material by greater or lesser degree of increased concentration of protein-bound hydroxyproline in sampled culture liquid against the control. As a control sample it is useful to apply culture liquid in which one could observe the tested bioplastic material for 4 d but no fibroblasts. The innovation is simple and enables to quantitatively evaluate the stimulation of collagenogenesis with bioplastic materials without applying any laboratory animals.

EFFECT: higher accuracy of evaluation.

FIELD: pharmaceutical chemistry, pharmacy.

SUBSTANCE: invention proposes a biotransplant representing a suspension of autologous fibroblasts with the cloning effectiveness 40-60% in an autologous serum. Also, invention relates to a method for preparing the claimed biotransplant that comprises culturing autologous fibroblasts under the definite conditions and selection of cells showing the lesser adhesion degree to a surface, and a method for correction of human soft tissue defects by the definite schedule. Invention provides the high therapeutic effect and absence of adverse effects and complications. Invention can be used in treatment of parodontopathy, in plastic medicine in treatment age changes of face skin and others disorders, in treatment of alopecia of non-androgenic origin.

EFFECT: improved method of correction, valuable biological and medicinal properties of biotransplant.

10 cl, 3 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with local chemotherapy of malignant cerebral tumors. Thus, after removing the tumor one should apply a collagen hemostatic sponge with a cavity inside it with a powder-like chemopreparation into tumor's bed, then the cavity should be covered with another fragment of collagen sponge. The innovation enables to minimize toxic manifestations of chemotherapy at applying maximal concentration of anti-tumor preparation.

EFFECT: higher efficiency.

6 dwg, 2 ex

FIELD: chemical engineering.

SUBSTANCE: method involves pretreating bone tissue of stock-farm animals, comminuting it, precipitating the end product and drying it by lyophilizing. The bone tissue is degreased with alcohol-ether mixture. Demineralization 0.5 and HCl is carried out after grinding during 20 h. Non-resolvable matrix is subjected to proteolysis in HCl of pH=2.0 in pepsin presence at 37°C during 18 h. Then it is centrifuged at 40000g. The end product is precipitated from supernatant with ammonium sulfate to 25% saturation and centrifuged at 6000g. The precipitate is lyophilized against distilled water and chromatographically purified using CM-Sephadex at pH=4.8 and dried with lyophilization.

EFFECT: low cost collagen production; high purity cosmetic preparation production.

2 dwg

FIELD: biomedical engineering.

SUBSTANCE: device has composite materials containing biologically active microparticles stimulating human bone tissue regeneration. Silicon, calcium and phosphorus particles combination is used in given carcasses as biologically active substance stimulating human osteoblast proliferation and differentiation and promoting osteogenesis and new bone calcification. Beside that, organic polymer is used in given carcasses as carrier having three-dimensional structure and external anatomical shape. It shows several properties compatible with bone regeneration and blood vessel neogenesis.

EFFECT: enhanced effectiveness of treatment; improved safety and cost-effectiveness.

27 cl, 6 dwg, 1 tbl

Up!